Premier Alternatives

Immunofoco Biotechnology

Shanghai, China · Founded 2020 · In IPO Registration

Developer and manufacturer of CAR-T cell therapies and innovative treatment platforms designed for solid tumors and hematological cancers. Immunofoco Biotechnology is based in Shanghai, China and was founded in 2020. Its last reported valuation was $298 million in Feb 2026. It has raised $139 million.

Last reported valuation
$298.1M
Oct 2026
Priced at
—
Total raised
$138.8M
Last round
—

Immunofoco Biotechnology key facts

as of Oct 2026
  • Developer and manufacturer of CAR-T cell therapies and innovative treatment platforms designed for solid tumors and hematological cancers.
  • Immunofoco Biotechnology is valued at approximately $298.1M as of Oct 2026 (last reported valuation).
  • It has raised $138.8M; the latest was IPO in Feb 2026.
  • Notable investors include ZhenFund, Green Pine Capital Partners, Shenzhen Nanshan Strategic Emerging Industry Investment, Orinno Capital, Beijing Delian Yuntong Investment Management Company — 27 tracked in total.
  • Status: In IPO Registration.
Last reported valuation
LOW confidence
$298.1M

Immunofoco Biotechnology's last reported valuation, Feb 2026. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Immunofoco Biotechnology with a free account
  • ·The complete investor list: 27 names
  • ·Watch Immunofoco Biotechnology: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Immunofoco Biotechnology funding rounds

No rounds on record

No funding rounds for Immunofoco Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Immunofoco Biotechnology valuation

Immunofoco Biotechnology's last reported valuation was $298 million in Feb 2026. No priced round, secondary trade or fund mark has surfaced since.

Immunofoco Biotechnology investors

27 investors are on record for Immunofoco Biotechnology, including ZhenFund, Green Pine Capital Partners, Shenzhen Nanshan Strategic Emerging Industry Investment and Orinno Capital. By type, the record holds 5 venture capital firms.

About Immunofoco Biotechnology

Developer and manufacturer of CAR-T cell therapies and innovative treatment platforms designed for solid tumors and hematological cancers. The company provides clinical-stage drug candidates and off-the-shelf solutions, enabling oncology patients and healthcare providers with enhanced therapeutic options, improved survival outcomes, and more accessible cellular immunotherapy.

Sector
Healthcare
HQ
Shanghai, China
Founded
2020
Employees
105
Ownership
In IPO Registration

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.